Publications

Lizarraga L, Suter GW, Lambert JC, Patlewicz G, Zhao JQ, Dean JL, Kaiser P. 2023. Advancing the science of a read-across framework for evaluation of data poor chemicals incorporating systematic and new approach methods. Regul Toxicol Pharm 137(Jan):105293; doi: 10.1016/j.yrtph.2022.105293. PMID: 36414101.

Borghoff SJ, Cohen SS, Jiang X, Lea IA, Klaren WD, Chappell GA, Britt JK, Rivera BN, Choksi NY, Wikoff DS. 2023. Updated systematic assessment of human, animal and mechanistic evidence demonstrates lack of human carcinogenicity with consumption of aspartame. Food Chem Toxicol 172(Feb):113549; doi: 10.1016/j.fct.2022.113549. PMID: 36493943.

Bullano M, Cool C, Schultz BG, Durgapal S, Sacks N, Liu Y, Kee R, Batt K. 2023. Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert Rev Phamacoecon Outcome Res 23(2):225-230; doi: 10.1080/14737167.2023.2160705. PMID: 36537696.

Doepker C, Movva N, Cohen SS, Wikoff DS. 2022. Benefit-risk of coffee consumption and all-cause mortality: A systematic review and disability adjusted life year analysis. Food Chem Toxicol 170(Dec):113472; doi: 10.1016/j.fct.2022.113472. PMID: 36243217.

Boles C, Zisook R, Buerger AN, Hamaji C, Mathis C, Lauer D, et al. 2022. Semi-quantitative microbial risk assessment: A narrative review and proposed framework for health and safety practitioners. J Pub Health Emerg 6(Dec 25):34; doi: 10.21037/jphe-22-1.

Broome CM, Hooda N, Su J, Jiang X, Nicholson G, Frankenfeld CL, Iglesias-Rodriguez M, Fryzek J, Patel Parija. 2022. Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: Analysis of an integrated claim-clinical cohort in the United States. PLoS One 17(12):e0276617; doi: 10.1371/journal.pone.0276617. PMID: 36520848.

Kato Y, Lim AY, Sakolish C, Valdiviezo A, Moyer HL, Hewitt P, Bajaj P, Han G, Rusyn I. 2022. Analysis of reproducibility and robustness of OrganoPlate^® 2-lane 96, a liver microphysiological system for studies of pharmacokinetics and toxicological assessment of drugs. Toxicol in Vitro 85(Dec):105464; doi: 10.1016/j.tiv.2022.105464. PMID: 36057418.

Godínez-Oviedo A, Sampedro F, Bowman JP, Garcés-Vega FJ, Hernández-Iturriaga M. 2022. Genotypic and phenotypic quantitative microbial risk assessment model of human salmonellosis related to the consumption of chicken meat in the central region of Mexico. Food Res Int 162(A):111901; doi: 10.1016/j.foodres.2022.111901. PMID: 36461177.

Shah I, Bundy J, Chambers B, Everett L, Haggard D, Harrill J, Judson R, Nyffeler J, Patlewicz G. 2022. Navigating transcriptomic connectivity mapping workflows to link chemicals with bioactivities. Chem Res Toxicol 35(11):1929-1949; doi: 10.1021/acs.chemrestox.2c00245. PMID: 36301716.

Yao W, Jensen I, Claussen M, Dandurand K, Buffington B, Fuentes D, Mikhael M. 2022. Health economics of selective early rescue surfactant administration and standard surfactant administration for newborns with respiratory distress syndrome. J Pediatr Pharmacol Ther 27(8):695–702; doi:  10.5863/1551-6776-27.8.695.

Zwickl CM, Graham JC, Holly RA, Bassan A, Ahlberg E, Amberg A, Anger LT,.., Patlewicz G, et al. 2022. Principles and procedures for assessment of acute toxicity incorporating in silico methods. Comput Toxicol 24(Nov):100237; doi: 10.1016/j.comtox.2022.100237. PMID: 36818760.

Patlewicz G, Nelms MN, Rua D. 2022. Evaluating the utility of the Threshold of Toxicological Concern (TTC) and its exclusions in the biocompatibility assessment of extractable chemical substances from medical devices. Comput Toxicol 24(Nov):100246; doi: 10.1016/j.comtox.2022.100246. PMID: 36405647.

Cronin MTD, Bauer FJ, Bonnell M, Campos B, Ebbrell DJ, Firman JW, Gutsell S, Hodges G, Patlewicz G, et al. 2022. A scheme to evaluate structural alerts to predict toxicity–Assessing confidence by characterizing uncertainties. Regul Toxicol Pharmacol 135(Nov):105249; doi: 10.1016/j.yrtph.2022.105249. PMID: 36041585.

Patlewicz G, Richard AM, Williams AJ, Judson RS, Thomas RS. 2022. Towards reproducible structure-based chemical categories for PFAS to inform and evaluate toxicity and toxicokinetic testing. Comput Toxicol 24(Nov):100250; doi: 10.1016/j.comtox.2022.100250. PMID: 36969381.

Gillezeau C, Movva N, van Gerwen M, Rabon-Stith K, Shire N, Brohawn PZ, Taioli E, Fryzek J. 2022. Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients. PLoS One 17(8):e0271339; doi: 10.1371/journal.pone.0271339. PMID: 36040901; PMCID: PMC9426882.

Cohen SS, Bylsma LC, Movva N, Alexander DD. 2022. Theoretical attributable risk analysis and Disability Adjusted Life Years (DALYs) based on increased dairy consumption. BMC Public Health 22(1):1625; doi: 10.1186/s12889-022-14042-7. PMID: 36030208.

Heintz MM, Chappell GA, Thompson CM, Haws LC. 2022. Evaluation of transcriptomic responses in livers of mice exposed to the short-chain PFAS compound HFPO-DA. Front Toxicol 4(Jun 27):937168; doi: 10.3389/ftox.2022.937168. PMID: 35832492.

Goyak KO, Sarang SS, Franzen A, Borghoff SJ, Ryman-Rasumssen JP. 2022. Adverse outcome pathway (AOP): α2u-globulin nephropathy and kidney tumors in male rats. Crit Rev Toxicol 52(5):345-357; doi: 10.1080/10408444.2022.2082269. PMID: 35862579.

Foster MJ, Patlewicz G, Shah I, Haggard DE, Judson RS, Paul Friedman K. 2022. Evaluating structure-based activity in a high throughput assay for steroid biosynthesis. Comput Toxicol 24(Nov):100245; doi: 10.1016/j.comtox.2022.100245. PMID: 37841081.